Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5180)
All Articles published online
|
Publishing Process of This Article
|
Dec 26, 2020 (publication date) through Feb 8, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273 [PMID: 33392307 DOI: 10.12998/wjcc.v8.i24.6264] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm |
| Number | Citing Articles |
| 1 |
Ryota Horibe, Motohiro Yokota, Koujiro Uemura, Midori Hashimoto, Naoki Kawagishi, Kaoru Nishiyama. <i>De novo</i> Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer. Internal Medicine 2024; 63(12): 1797 doi: 10.2169/internalmedicine.2731-23
|
| 2 |
Maki Ohkubo, Emiko Seo, Kosuke Doki, Yoshiharu Suzuki, Ikuo Sekine, Masato Homma. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation. Biological and Pharmaceutical Bulletin 2024; 47(5): 941 doi: 10.1248/bpb.b23-00907
|
| 3 |
Ciro Celsa, Giacomo E. M. Rizzo, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Gabriele Rancatore, Pietro Graceffa, Giuseppe Falco, Salvatore Petta, Giuseppe Cabibbo, Vincenza Calvaruso, Antonio Craxì, Calogero Cammà, Vito Di Marco. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis. Liver International 2024; 44(11): 2890 doi: 10.1111/liv.16064
|